Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThe lancet respiratory medicine, 2022-10, Vol.10 (10), p.972 [Peer Reviewed Journal]Copyright © 2022 Elsevier Ltd. All rights reserved. ;EISSN: 2213-2619 ;DOI: 10.1016/S2213-2600(22)00215-6 ;PMID: 35817072Digital Resources/Online E-Resources |
2 |
Material Type: Article
|
![]() |
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndromeBlood, 2023-03, Vol.141 (9), p.971-983 [Peer Reviewed Journal]2023 The American Society of Hematology ;2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 The American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2022018546 ;PMID: 36399712Full text available |
3 |
Material Type: Article
|
![]() |
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled TrialThe American journal of psychiatry, 2022-02, Vol.179 (2), p.132-141 [Peer Reviewed Journal]Copyright © 2022 by the American Psychiatric Association 2022 ;Copyright American Psychiatric Association Feb 2022 ;ISSN: 0002-953X ;EISSN: 1535-7228 ;DOI: 10.1176/appi.ajp.2021.20101429 ;PMID: 34711062Full text available |
4 |
Material Type: Article
|
![]() |
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2Neurology, 2020-03, Vol.94 (13), p.e1365-e1377 [Peer Reviewed Journal]2020 American Academy of Neurology ;Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. ;Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 2020 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000009169 ;PMID: 32209650Full text available |
5 |
Material Type: Article
|
![]() |
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trialEuropean heart journal, 2016-08, Vol.37 (30), p.2406-2413 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehw171 ;PMID: 27161611Full text available |
6 |
Material Type: Article
|
![]() |
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJournal of clinical oncology, 2023-01, Vol.41 (3), p.528-540 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.22.00343 ;PMID: 35998300Full text available |
7 |
Material Type: Article
|
![]() |
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1636-1646 [Peer Reviewed Journal]2020 International Association for the Study of Lung Cancer ;Copyright © 2020 by the International Association for the Study of Lung Cancer ;Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. ;ISSN: 1556-0864 ;EISSN: 1556-1380 ;DOI: 10.1016/j.jtho.2020.07.014 ;PMID: 32781263Full text available |
8 |
Material Type: Article
|
![]() |
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side EffectsThe New England journal of medicine, 2020-11, Vol.383 (22), p.2182-2184 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2031173 ;PMID: 33196154Full text available |
9 |
Material Type: Article
|
![]() |
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialClinical cancer research, 2020-04, Vol.26 (7), p.1586-1594 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-18-1140 ;PMID: 32034072Full text available |
10 |
Material Type: Article
|
![]() |
Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control TrialThe American journal of gastroenterology, 2020-07, Vol.115 (7), p.1055 [Peer Reviewed Journal]EISSN: 1572-0241 ;DOI: 10.14309/ajg.0000000000000661 ;PMID: 32618656Full text available |
11 |
Material Type: Article
|
![]() |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe lancet oncology, 2017-09, Vol.18 (9), p.1274-1284 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 1, 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30469-2 ;PMID: 28754483Full text available |
12 |
Material Type: Article
|
![]() |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of clinical oncology, 2017-11, Vol.35 (32), p.3638-3646 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.75.6155 ;PMID: 28968163Full text available |
13 |
Material Type: Article
|
![]() |
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesThe New England journal of medicine, 2019-10, Vol.381 (18), p.1718-1727 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1908681 ;PMID: 31566307Full text available |
14 |
Material Type: Article
|
![]() |
A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia ControlOptometry and vision science, 2019-08, Vol.96 (8), p.556 [Peer Reviewed Journal]EISSN: 1538-9235 ;DOI: 10.1097/OPX.0000000000001410 ;PMID: 31343513Digital Resources/Online E-Resources |
15 |
Material Type: Article
|
![]() |
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathyKidney international, 2023-02, Vol.103 (2), p.391-402 [Peer Reviewed Journal]2022 International Society of Nephrology ;Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. ;ISSN: 0085-2538 ;EISSN: 1523-1755 ;DOI: 10.1016/j.kint.2022.09.017 ;PMID: 36270561Digital Resources/Online E-Resources |
16 |
Material Type: Article
|
![]() |
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialThe lancet respiratory medicine, 2021-12, Vol.9 (12), p.1407 [Peer Reviewed Journal]Copyright © 2021 Elsevier Ltd. All rights reserved. ;EISSN: 2213-2619 ;DOI: 10.1016/S2213-2600(21)00331-3 ;PMID: 34480861Digital Resources/Online E-Resources |
17 |
Material Type: Article
|
![]() |
Mosaic human preimplantation embryos and their developmental potential in a prospective, non-selection clinical trialAmerican journal of human genetics, 2021-12, Vol.108 (12), p.2238-2247 [Peer Reviewed Journal]2021 The Author(s) ;Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. ;2021 The Author(s) 2021 ;ISSN: 0002-9297 ;EISSN: 1537-6605 ;DOI: 10.1016/j.ajhg.2021.11.002 ;PMID: 34798051Full text available |
18 |
Material Type: Article
|
![]() |
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2022-02, Vol.386 (6), p.509-520 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2116044 ;PMID: 34914868Digital Resources/Online E-Resources |
19 |
Material Type: Article
|
![]() |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet (British edition), 2021-01, Vol.397 (10269), p.99-111 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32661-1 ;PMID: 33306989Full text available |
20 |
Material Type: Article
|
![]() |
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225Digital Resources/Online E-Resources |